| Literature DB >> 34621410 |
Jirarat Jiratham-Opas1, Narawudt Prasertwitayakij1, Teerapat Nantsupawat1, Wanwarang Wongcharoen1.
Abstract
BACKGROUND: Cardiac implantable electronic device (CIED) implantation rate has been increasing worldwide. Despite proper surgical technique and preincisional intravenous antibiotics, the incidence of infected CIED remains high and leads to serious complications. When encountered with CIED infection, complete CIED system removal is indicated. Several lead extraction approaches have shown a high success rate. However, the facilities are limited in Thailand. In our current practice, we perform lead extraction using the Dotter basket snare femoral approach as our primary method. There are no prior data on this countertraction-assisted transfemoral technique. Therefore, we aim to study the procedural outcome of countertraction-assisted transfemoral lead removal technique of CIED infection in Thai patients.Entities:
Keywords: CIED infection; countertraction‐assisted femoral lead extraction; lead removal
Year: 2021 PMID: 34621410 PMCID: PMC8485811 DOI: 10.1002/joa3.12574
Source DB: PubMed Journal: J Arrhythm ISSN: 1880-4276
FIGURE 1RAO view showing a 4‐mm tip ablation catheter through steerable sheath looped into the right ventricular (RV) apex forming primary (open arrow) and secondary curves (close arrow) of the telescopic countertraction system
FIGURE 2RAO view showing a second 4‐mm tip ablation catheter, from short vascular sheath, advanced over the target defibrillator lead (white arrow). The Dotter basket snare, via the remaining steerable sheath, was then used to grasp the ablation catheter shaft from another side, which ensured capturing the target lead
FIGURE 3RAO view showing that the target lead was pulled down through which the distal lead tip was freed from the myocardium. Countertraction system stayed at their positions
FIGURE 4Microbiological data
Baseline characteristics
| Baseline characteristics | Total (N = 35) |
|---|---|
| Age, years | 64.4 ± 13.5 |
| Gender (M:F) | 23:12 (64:35%) |
| Comorbidities | |
| Coronary artery disease | 6 (17%) |
| Heart failure with reduced ejection fraction | 11 (30%) |
| Atrial fibrillation | 12 (33%) |
| Device indication | |
| Sick sinus syndrome | 14 (41%) |
| Atrioventricular block | 19 (55%) |
| Primary SCD prevention | 2 (5.8%) |
| Secondary SCD prevention | 7 (20.5%) |
| Types of CIED infection | |
| Single‐chamber pacemaker | 5 [14.3%] |
| Dual‐chamber pacemaker | 15 [42.9%] |
| AICD | 10 [28.6%] |
| CRT | 2 [5.7%] |
| Pulse generator change | 2 [5.7%] |
| Upgrade procedure | 1 [2.8%] |
| CIED infection types | |
| Early (<30 days postimplant) | 8 [22.8%] |
| Late (30‐364 days postimplant) | 8 [22.8%] |
| Delay infection (>364 days postimplant) | 19 [54.3%] |
| Target leads | 56 leads |
| Atrial pacing leads | 19 leads |
| RV pacing leads | 22 leads |
| AICD dual coil | 10 leads |
| AICD single coil | 3 |
| CS leads | 2 leads |
Values are mean ± SD or n (%).
Abbreviations: AICD, automatic implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; CS, coronary sinus; RV, right ventricle; SCD, sudden cardiac death.
(A) Procedural and (B) clinical lead success and failure rate
| (A) Procedural success and failure rate | |
|---|---|
| Procedural outcomes | Total (N = 35) |
| Complete procedural success | 33 (94.3%) |
| Procedural failure | 2 (5.7%) |
| Procedure time | Minutes [mean ± SD] |
| Explant | 13‐60 [35 ± 15] |
| Extraction | 42‐240 [104 ± 65] |
| Complete lead removal | Total leads 56 leads |
| Atrial lead (19 leads) | 19 leads (100%) |
| RV pacing lead (22 leads) | 22 leads (100%) |
| AICD dual coil (10 leads) | 8 leads (80%) |
| AICD single coil (3 leads) | 3 leads (100%) |
| CS lead (2 leads) | 2 leads (100%) |
| Lead dwell time | Month (mean ± SD) |
| Explant | 1‐70 [20 ± 24] |
| Extract | 52‐169 [88 ± 35] |
Abbreviations: AICD, automatic implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; CS, coronary sinus; RV, right ventricle.
Clinical characteristics of failure cases
| Case 1 | Case 2 | |
|---|---|---|
| Age, years | 43 | 68 |
| Gender | Male | Male |
| Types of device | AICD for secondary prevention | AICD for secondary prevention |
| Underlying diseases | Brugada syndrome | Ischemic cardiomyopathy, paroxysmal atrial fibrillation, essential hypertension, CKD stage IV |
| Implant time, months | 43 | 65 |
Abbreviations: AICD, automatic implantable cardioverter defibrillator; CKD, chronic kidney disease.
Adverse events
| Adverse events | n (%) |
|---|---|
| Procedure‐related complications | |
| Right femoral vein laceration | 1 (2.8) |
| Right ventricle inversion | 1 (2.8) |
| Non‐procedure‐related complications | |
| CIED infection‐related death | 2 (5.7) |
| Nosocomial infection‐related death | 1 (2.8) |
| CIED‐related systemic infection | 2 (5.7) |
Abbreviation: CIED, cardiovascular implantable electronic device.